drugset

drugset / Trial / NCT00326326

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

NCT00326326 ↗

Phase 2 Completed 84 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes

Timeline

Start: 2006-07
Primary completion: —
Completion: 2007-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CP-778,875	Small molecule	—	—

Indications